healthNewsغير مصنف

Amgen’s Krypolis fails newly diagnosed multiple myeloma study

(Reuters) – Amgen Inc said on Tuesday its multiple myeloma drug, Kyprolis, was not found superior to Takeda Pharmaceutical Co Ltd’s Velcade in a late-stage study in previously untreated patients.

اظهر المزيد

مقالات ذات صلة

زر الذهاب إلى الأعلى